• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续肾脏替代治疗中的枸橼酸盐抗凝:滤器相关结局的多中心儿科重症监护病房研究

Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes.

作者信息

Kihtir Hasan S, Duyu Muhterem, Mementoglu Mehmet E, Tolunay Ilknur, Kendirli Tanil, Ekinci Faruk, Botan Edin, Ongun Ebru A, Asik Ayse, Gun Emrah, Ucmak Hacer, Sevketoglu Esra, Yildizdas Dincer

机构信息

Department of Pediatric Critical Care, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey.

Department of Pediatric Critical Care, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.

出版信息

Pediatr Crit Care Med. 2025 Feb 1;26(2):e216-e226. doi: 10.1097/PCC.0000000000003661. Epub 2024 Dec 19.

DOI:10.1097/PCC.0000000000003661
PMID:39699267
Abstract

OBJECTIVES

To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU.

DESIGN

Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023.

SETTING

Seven PICUs in Turkey.

PATIENTS

PICU admissions in need of CRRT, 28 days to 18 years old.

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (≥ 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation.

CONCLUSIONS

Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL.

摘要

目的

研究儿科重症监护病房(PICU)中连续性肾脏替代治疗(CRRT)的枸橼酸盐抗凝效果。

设计

对2022年1月1日至2023年6月1日收集的经整理的多中心数据集进行事后分析。

地点

土耳其的7个PICU。

患者

需要进行CRRT的PICU住院患者,年龄在28天至18岁之间。

干预措施

无。

测量指标及主要结果

在73名患者使用的128个滤器中,限制在72小时的有效滤器寿命(EFL)中位数(四分位间距[IQR])为40.5小时(IQR,21 - 58小时);总EFL中位数为59小时(IQR,28 - 89小时)。对初始枸橼酸盐输注剂量(CID)以及EFL是否达到72小时的受试者工作特征曲线分析确定,初始CID的临界水平为每升患者血流量大于2.64 mmol枸橼酸盐(mmol/L-bf)。正如预期的那样,按初始CID分类的两个滤器组(≥2.7 vs. <2.7 mmol/L-bf)显示,接受较高初始剂量的儿童使用的滤器总EFL更长(72小时[IQR,48 - 104小时] vs. 38.5小时[IQR,18 - 84小时];p = 0.03)。我们未能确定超过24或48小时的CRRT与枸橼酸盐蓄积的更高几率(优势比[OR],95%可信区间)之间存在关联(OR,2.23;95%可信区间,0.82 - 6.13;p = 0.118或OR,1.78;95%可信区间,0.84 - 3.8;p = 0.134)。然而,我们不能排除枸橼酸盐蓄积几率高达6.1倍或3.8倍的情况;值得注意的是,超过72小时的CRRT与枸橼酸盐蓄积的更高几率相关(OR,2.17;95%可信区间,1.01 - 4.68;p = 0.04)。128个滤器中有8个(6.3%;95%可信区间,3 - 11.4%)发生了枸橼酸盐封管综合征,且在未终止CRRT的情况下得到解决。多变量分析显示,患者初始乳酸浓度较高与发生枸橼酸盐蓄积的风险增加18%(95%可信区间,7 - 30%)相关。

结论

CRRT的枸橼酸盐抗凝对儿童是一种选择。选择初始CID大于或等于2.7 mmol/L-bf可提供更长的EFL,但存在枸橼酸盐蓄积的潜在风险。需要对初始CID和EFL持续时间进行进一步研究。

相似文献

1
Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes.持续肾脏替代治疗中的枸橼酸盐抗凝:滤器相关结局的多中心儿科重症监护病房研究
Pediatr Crit Care Med. 2025 Feb 1;26(2):e216-e226. doi: 10.1097/PCC.0000000000003661. Epub 2024 Dec 19.
2
Epoprostenol (Prostacyclin Analog) as a Sole Anticoagulant in Continuous Renal Replacement Therapy for Critically Ill Children With Liver Disease: Single-Center Retrospective Study, 2010-2019.依前列醇(前列环素类似物)作为唯一抗凝剂在连续肾脏替代治疗中用于危重症肝病儿童:2010-2019 年单中心回顾性研究。
Pediatr Crit Care Med. 2024 Jan 1;25(1):15-23. doi: 10.1097/PCC.0000000000003371. Epub 2023 Sep 12.
3
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.局部枸橼酸抗凝与全身肝素抗凝对连续性肾脏替代治疗中急性肾损伤危重症患者透析滤器寿命和死亡率的影响:一项随机临床试验。
JAMA. 2020 Oct 27;324(16):1629-1639. doi: 10.1001/jama.2020.18618.
4
A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy.比较依前列醇、肝素和柠檬酸盐在接受连续肾脏替代治疗的儿童中的抗凝疗效和安全性。
Blood Purif. 2024;53(10):838-846. doi: 10.1159/000540302. Epub 2024 Jul 18.
5
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.药物干预预防连续性肾脏替代治疗中体外循环凝血。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
6
Generalization of regional citrate anticoagulation for continuous renal replacement therapy is not associated with an increased rate of severe complications.
J Crit Care. 2025 Jun;87:155032. doi: 10.1016/j.jcrc.2025.155032. Epub 2025 Feb 14.
7
Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure.区域枸橼酸盐抗凝在小儿肝衰竭患者连续性肾脏替代治疗中的应用
PLoS One. 2017 Aug 8;12(8):e0182134. doi: 10.1371/journal.pone.0182134. eCollection 2017.
8
[Risk factors for citrate accumulation in patients with liver failure undergoing continuous renal replacement therapy with regional citrate anticoagulation].[接受局部枸橼酸抗凝持续肾脏替代治疗的肝衰竭患者枸橼酸蓄积的危险因素]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Feb;33(2):211-215. doi: 10.3760/cma.j.cn121430-20201102-00698.
9
Regional citrate anticoagulation versus LMWH anticoagulation for CRRT in liver failure patients without increased bleeding risk.局部枸橼酸抗凝与低分子肝素抗凝在无出血风险增加的肝衰竭患者连续性肾脏替代治疗中的应用比较。
Int J Artif Organs. 2024 Oct;47(10):756-764. doi: 10.1177/03913988241269492. Epub 2024 Aug 24.
10
Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation.接受局部枸橼酸盐抗凝持续肾脏替代治疗的危重症患者的高乳酸血症、乳酸动力学及枸橼酸盐蓄积预测
Crit Care Med. 2017 Sep;45(9):e941-e946. doi: 10.1097/CCM.0000000000002501.

引用本文的文献

1
Effect of sodium citrate anticoagulant solution in continuous veno-venous hemofiltration in critically ill children.枸橼酸钠抗凝溶液在危重症儿童连续性静脉-静脉血液滤过中的作用
BMC Pediatr. 2025 Jul 2;25(1):496. doi: 10.1186/s12887-025-05762-x.